GRCE Earnings — Grace Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
GRCE — Grace Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$2.45
Market Cap$37.9M
P/E—
52W Range$1.79 – $5.18
Next Earnings2026-06-22
About Grace Therapeutics, Inc. Common Stock
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
